<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Agree Realty Corp.</title>
	<atom:link href="http://www.stockbloghub.com/tag/agree-realty-corp/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BMY) Bristol-Myers Squibb Buyout of Medarex Update</title>
		<link>http://www.stockbloghub.com/2009/08/28/bmy-bristol-myers-squibb-buyout-of-medarex-update/13807</link>
		<comments>http://www.stockbloghub.com/2009/08/28/bmy-bristol-myers-squibb-buyout-of-medarex-update/13807#comments</comments>
		<pubDate>Fri, 28 Aug 2009 23:03:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADC]]></category>
		<category><![CDATA[Agree Realty Corp.]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13807</guid>
		<description><![CDATA[Yesterday, Bristol-Myers Squibb Co. (BMY) announced that its cash tender offer to purchase all outstanding shares of common stock of Medarex Inc. (MEDX) expired on Aug. 26.  The tender offer was not extended, unlike the previous instance when the offer originally scheduled to close on August 24 was extended by two days. The cash tender offer saw 87.7% of Medarex shares outstanding, or a total of 119 million shares, being tendered. With an objective of acquiring the remaining Medarex stock, Bristol announced a subsequent offering period from yesterday until August 31, 2009, unless extended. The Bristol management believes that the completion of the deal would be hastened if more than 90% Medarex shares are tendered. Even if the new tender offer fails to attain this goal, the deal is expected ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/bmy-bristol-myers-squibb-buyout-of-medarex-update/13807/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Co. announced Medarex Acquisition Cleared Review</title>
		<link>http://www.stockbloghub.com/2009/08/14/bmy-bristol-myers-squibb-co-announced-medarex-acquisition-cleared-review/12518</link>
		<comments>http://www.stockbloghub.com/2009/08/14/bmy-bristol-myers-squibb-co-announced-medarex-acquisition-cleared-review/12518#comments</comments>
		<pubDate>Fri, 14 Aug 2009 23:54:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADC]]></category>
		<category><![CDATA[Agree Realty Corp.]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12518</guid>
		<description><![CDATA[Bristol-Myers Squibb Co. (BMY) yesterday announced that the regulatory review period for its cash tender offer to acquire Medarex Inc. (MEDX) has expired. On July 28, 2009, Bristol-Myers had initiated an offer to buy all outstanding shares of common stock of Medarex for $16 per share. The clearance of the review, necessary under the anti-trust law, allows the $2.1 billion deal to proceed. With the Medarex acquisition, Bristol-Myers will acquire the UltiMAb Human Antibody Development System, which produces high affinity, fully human antibodies for use in a broad range of therapeutic areas Incorporatedluding immunology and oncology. Bristol-Myers will also acquire Medarex’s next-generation Antibody-Drug Conjugate (ADC) technology, which is a novel and proprietary platform that could open new fields in oncology drug development. Medarex’ pipeline includes seven antibodies in clinical trials ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/14/bmy-bristol-myers-squibb-co-announced-medarex-acquisition-cleared-review/12518/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RHB) RehabCare Group Inc. &#8211; Value &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/05/22/rhb-rehabcare-group-inc-value-zacks-rank-buy/7288</link>
		<comments>http://www.stockbloghub.com/2009/05/22/rhb-rehabcare-group-inc-value-zacks-rank-buy/7288#comments</comments>
		<pubDate>Fri, 22 May 2009 23:31:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospitals]]></category>
		<category><![CDATA[ADC]]></category>
		<category><![CDATA[Agree Realty Corp.]]></category>
		<category><![CDATA[Rehabcare Group Inc.]]></category>
		<category><![CDATA[RHB]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=7288</guid>
		<description><![CDATA[RehabCare Group Inc. (RHB), which provides rehabilitation services, continued its hot streak of earnings surprise as it beat for the 4th consecutive quarter. Revenue grew by 11.6% on strong demand for skilled nursing services. RHB trades at 12.5x forward earnings. Company Description RehabCare provides rehabilitation program management services at over 1,200 hospitals and skilled nursing facilities in 42 states. The company also operates freestanding rehabilitation hospitals and long-term acute care hospitals across the country. Revenue Jumped 11.6% in the First Quarter On May 5, RehabCare reported first quarter results which surprised on analysts&#8217; estimates by 54.84%, or 17 cents a share. Earnings per share were 48 cents compared to 25 cents per share in the year ago period. Analysts expected 31 cents. Revenue grew by 11.6% to $203.4 million compared ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/05/22/rhb-rehabcare-group-inc-value-zacks-rank-buy/7288/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

